Kyverna surges after IPO, and CEO lays out plans for cell therapy in immune diseases

Kyver­na Ther­a­peu­tics start­ed its first day as a pub­lic biotech on a strong note, with its shares $KYTX ris­ing more than 50% Thurs­day af­ter­noon af­ter pric­ing at $22 and rais­ing $319 mil­lion for the com­pa­ny. But don’t call the Nas­daq IPO an overnight suc­cess. It took five years to…#kyverna #kyvernavillage #gilead #aseriesbextension #unlock

Source: Reuters: Health - February 9, 2024 Category: Consumer Health News Source Type: news